Foundation Psychedelic Review — Issue Zero
FOUNDATION PSYCHEDELIC REVIEW · ISSUE ZERO · SEPTEMBER 2026
The Psychedelic Investment Landscape
What changed, which companies matter, where the evidence is strongest, where the access economics may break — and what would change our minds.
Research build last checked September 12, 2026. Educational research only; not individualized investment, legal, tax, or medical advice. Psychedelic therapeutics remain high-risk clinical-stage assets. Specific editor holdings/relationships disclosure is being finalized for the public launch; until then, treat this as a research preview.
Executive thesis
2026 looks less like a broad “psychedelic sector” trade and more like the beginning of institutional sorting. The important question is no longer whether altered-state therapeutics can produce meaningful clinical signals. Multiple late-stage programs now have positive Phase 3 readouts. The harder questions are which programs can survive regulatory review, fit into real clinical workflows, earn reimbursement, protect their economics, and finance commercialization without destroying shareholder value.
Three developments make the current window structurally different. First, the FDA finalized dedicated psychedelic-drug clinical-investigation guidance in July and will hold a public hearing on September 14 focused on potential future therapeutic use in supervised and supportive settings. Second, Compass Pathways is already in a rolling NDA process for COMP360 in treatment-resistant depression. Third, Lilly completed its acquisition of AtaiBeckley on September 11, giving the field a major-pharma validation event rather than another small-cap financing story.
Our working thesis is therefore institutionalization, not inevitability. Regulatory clarity is improving. Strategic interest is real. Clinical evidence is getting stronger. But treatment economics — provider time, monitored session burden, site throughput, reimbursement, durability, re-dosing and post-approval controls — may determine who ultimately captures value.
How we research the field
Foundation Psychedelic Review uses a claim-first architecture. Every major conclusion is separated into: claim → evidence → counter-evidence → uncertainty → commercial implication → falsifier. Primary sources take precedence over narrative consensus. FDA and SEC materials, trial registries, peer-reviewed publications, company filings and formal trial releases are the base layer; secondary reporting and AI synthesis are used to challenge interpretation, not replace evidence.
Evidence grades: A = regulator, SEC filing, peer-reviewed paper or primary trial record. B = company release/presentation. C = credible secondary source or derived estimate. D = hypothesis requiring validation. Cross-trial efficacy comparisons are treated cautiously because trial design, comparator, population, dosing, endpoints and support models differ.
1. Regulatory frame: the bottleneck is shifting
The FDA’s current posture is no longer “psychedelics are outside the normal drug-development system.” The agency has a finalized development guidance and a September 14 public hearing specifically addressing future therapeutic use in supervised/supportive settings. That does not guarantee approval for any product. It does mean the category is being forced into a more explicit regulatory framework.
The investable implication: regulatory uncertainty remains material, but the center of gravity is moving toward product-specific execution and post-approval delivery design. The winners may be those that can satisfy FDA evidence standards while minimizing the operational burden that comes with altered-state treatment.
Primary sources: FDA Psychedelic Drugs hub · September 14 FDA public hearing.
2. Company scorecards
Compass Pathways (NASDAQ: CMPS) — regulatory proximity
What matters: COMP360, a proprietary synthetic psilocybin formulation for treatment-resistant depression, has produced positive results in two Phase 3 trials. In COMP006, two 25 mg doses versus 1 mg comparator produced a 3.8-point mean treatment difference on MADRS at Week 6 (p<0.001). Compass reported durable benefit through at least six months across its Phase 3 program.
Regulatory/capital position: The FDA granted a rolling NDA submission/review request. Compass said in August that initial modules had been submitted, final submission remained targeted for Q4 2026, and it expected a potential commercial launch in the first half of 2027 subject to approval and DEA rescheduling. Cash at June 30 was $433 million, which the company says extends into 2028.
Investment question: Compass may be the cleanest near-term test of whether a classic psychedelic can cross from clinical efficacy into a scalable, reimbursable treatment model. The risk is that approval alone does not solve long supervised sessions, provider/site capacity or payer friction.
What changes our mind: a material regulatory setback; evidence that delivery requirements make site economics unattractive; reimbursement that fails to cover total treatment cost; or post-launch demand materially below clinical enthusiasm.
COMP006 Phase 3 results · Q2 2026 update
Definium Therapeutics (NASDAQ: DFTX) — evidence strength versus delivery burden
What matters: DT120 ODT (lysergide) has now generated two positive Phase 3 headline readouts across different indications. Emerge in major depressive disorder reported an 8.1-point placebo-adjusted MADRS improvement at Week 6 (p<0.0001) and 7.3 points at Week 12, with no serious adverse events or suicidality signal reported. Voyage in generalized anxiety disorder reported a 5.4-point placebo-adjusted HAM-A improvement at Week 12 (p<0.0001; Cohen’s d=0.81), with effects reported as early as Day 2.
Why it matters: Replicated late-stage signal across MDD and GAD is difficult to ignore. Definium therefore deserves to be evaluated as a psychiatric-platform story, not only a “psychedelic” ticker. The core commercialization question is whether the clinical effect justifies the monitoring and session burden of lysergide-based treatment.
Near-term catalyst: Panorama, a second Phase 3 GAD study, was expected to report topline results in September 2026. A confirming readout would meaningfully improve the replication story.
What changes our mind: failure to replicate in Panorama or Ascend; safety/post-marketing requirements that materially worsen site economics; or evidence that payers will not absorb the full cost of delivery despite strong efficacy.
Emerge Phase 3 filing · Voyage Phase 3 filing
Helus Pharma (NASDAQ: HELP) — next-generation delivery thesis
What matters: HLP003, a proprietary deuterated psilocin analogue for adjunctive treatment of major depressive disorder, has FDA Breakthrough Therapy Designation. The Phase 3 APPROACH trial completed enrollment of 223 participants; topline data are targeted for Q4 2026. EMBRACE, the second pivotal study, continues enrollment, with EXTEND collecting longer-term safety, durability and re-dosing data.
Investment question: Helus is a useful test of the proposition that next-generation molecules can preserve therapeutic benefit while improving the practical treatment model. That thesis is appealing, but Phase 3 confirmation matters more than pharmacology narrative.
What changes our mind: APPROACH fails its primary endpoint; durability does not reproduce under controlled Phase 3 conditions; or the real-world delivery model does not materially improve clinic throughput versus earlier psychedelic programs.
APPROACH enrollment/update · August 2026 business update
GH Research (NASDAQ: GHRS) — short-acting optionality with earlier regulatory risk
What matters: GH001 is an inhaled mebufotenin program being advanced toward a global pivotal program in treatment-resistant depression. GH reported in August that the FDA viewed its CMC and device plans as appearing Phase 3-ready, while discussions on pivotal design continued. The company held $362.7 million in cash, cash equivalents and marketable securities at June 30, 2026.
Investment question: If a very short-acting serotonergic treatment can produce robust, durable benefit, care-delivery economics could look materially different from longer monitored sessions. But GH is not yet at Compass-level regulatory proximity or Definium-level Phase 3 replication. The commercial upside is therefore paired with greater evidence and execution uncertainty.
What changes our mind: pivotal design adds unexpected operational burden; Phase 2 efficacy fails to reproduce; device/CMC requirements delay the program; or the assumed throughput advantage fails to translate into better provider economics.
AtaiBeckley / Eli Lilly — strategic validation, no longer a standalone pure play
What matters: Lilly completed its acquisition of AtaiBeckley on September 11, 2026. AtaiBeckley’s lead program, BPL-003, is being developed for treatment-resistant depression. For the sector, the transaction matters less as a ticker idea now and more as evidence that a global pharmaceutical company is willing to underwrite this therapeutic architecture.
Investment question: Strategic validation can lower the perceived “category risk” for the entire field, but it does not validate every molecule or valuation. The stronger implication is that assets with differentiated efficacy, delivery and IP may become acquisition targets before they mature into standalone commercial companies.
3. Cross-company lens
| Program | Strongest current evidence | Near-term catalyst | Commercial question |
|---|---|---|---|
| COMP360 / Compass | Two positive Phase 3 TRD trials; rolling NDA | Final NDA modules Q4 2026 | Can long supervised treatment fit reimbursement + site throughput? |
| DT120 / Definium | Positive Phase 3 MDD + GAD readouts | Panorama GAD readout expected Sep 2026 | Does very strong efficacy outweigh session burden? |
| HLP003 / Helus | Phase 2 durability + BTD; Phase 3 enrolled | APPROACH topline Q4 2026 | Does next-gen design improve practical delivery? |
| GH001 / GH Research | Phase 2b TRD + FDA CMC/device progress | Pivotal-program initiation targeted 2026 | Can short acting become a true economic advantage? |
| BPL-003 / Lilly | Strategic acquisition + late-stage program | Phase 3 progression under Lilly | Can big-pharma infrastructure accelerate adoption? |
Important: This matrix is not a ranking and should not be used to compare efficacy numerically across trials.
4. The variable we think the market may underweight: care economics
Most biotech models focus on probability of approval, eligible population, price and market share. Psychedelic therapeutics add another layer: the clinic itself becomes part of the product. The number of monitored hours, staffing ratio, facility utilization, prescriber workflow, preparation/follow-up, durability and repeat-dosing frequency can materially change the gross economic value of an otherwise effective drug.
That means a modestly less dramatic molecule with a far easier treatment workflow could ultimately create more enterprise value than a clinically spectacular therapy that is difficult to deliver. Conversely, a very large and durable clinical effect may justify an expensive care model if payers and providers can capture downstream savings. This is why our research will track efficacy and delivery economics as separate variables.
5. Catalyst calendar
- September 14, 2026: FDA public hearing on potential future therapeutic use of psychedelic drugs.
- September 2026: Definium Panorama Phase 3 GAD topline expected.
- Q4 2026: Helus APPROACH Phase 3 MDD topline expected.
- Q4 2026: Compass expects to complete final COMP360 NDA modules.
- 2026: GH Research targets initiation of a GH001 pivotal program, subject to regulatory alignment.
- Q4 2026: Lilly/AtaiBeckley had indicated BPL-003 Phase 3 advancement as a key next step.
6. Current conviction map — research priorities, not buy/sell calls
Closest regulatory test: Compass. Strongest multi-indication Phase 3 signal: Definium. Near-term next-generation readout: Helus. Highest short-acting delivery optionality among this core set: GH Research. Strongest strategic-category validation: Lilly’s acquisition of AtaiBeckley.
We are deliberately not collapsing these into one score. A “best drug,” “best company,” and “best security at today’s valuation” can be three different answers. Paid issues of Foundation Psychedelic Review will therefore add valuation, financing runway, dilution sensitivity, catalyst probability, access economics and thesis-change triggers to the clinical work.
7. What we are watching next
The next issue will update the landscape after the September 14 FDA hearing and incorporate any new Definium Panorama data. We will also begin a structured valuation layer: enterprise value, cash-adjusted valuation, probability-weighted catalyst tree, financing runway, dilution scenarios and a care-economics model for each lead program.
The goal is not to manufacture certainty. It is to make uncertainty legible.
— Foundation Labs